Sagent Pharmaceuticals, Inc. has introduced oxaliplatin injection, USP,
an antineoplastic agent, now in two liquid presentations. According to
IMS, for the 12 months ending July 2014, the US market for oxaliplatin
approximated $102 million. As with all products in Sagent's portfolio,
oxaliplatin features Sagent's PreventIV MeasuresSM packaging and
labeling, designed to help reduce the risk of medication errors.
Oxaliplatin injection, USP, used in combination with infusional 5-fluorouracil/leucovorin, is indicated for adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor and for treatment of advanced colorectal cancer.
Sagent Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectables.
Oxaliplatin injection, USP, used in combination with infusional 5-fluorouracil/leucovorin, is indicated for adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor and for treatment of advanced colorectal cancer.
Sagent Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectables.
No comments:
Post a Comment